N

NewAmsterdam Pharma Company NV
NASDAQ:NAMS

Watchlist Manager
NewAmsterdam Pharma Company NV
NASDAQ:NAMS
Watchlist
Price: 31.86 USD -2.54% Market Closed
Market Cap: 3.6B USD

Wall Street
Price Targets

NAMS Price Targets Summary
NewAmsterdam Pharma Company NV

Wall Street analysts forecast NAMS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NAMS is 49.74 USD with a low forecast of 37.37 USD and a high forecast of 63 USD.

Lowest
Price Target
37.37 USD
17% Upside
Average
Price Target
49.74 USD
56% Upside
Highest
Price Target
63 USD
98% Upside
NewAmsterdam Pharma Company NV Competitors:
Price Targets
ANAB
AnaptysBio Inc
21% Upside
ZBIO
Zenas Biopharma Inc
126% Upside
603392
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
9% Upside
301080
Acrobiosystems Co Ltd
26% Upside
002007
Hualan Biological Engineering Inc
22% Upside
ORGO
Organogenesis Holdings Inc
113% Upside
HRTX
Heron Therapeutics Inc
210% Upside
1801
Innovent Biologics Inc
20% Upside

Revenue
Forecast

Revenue Estimate
NewAmsterdam Pharma Company NV

The compound annual growth rate of NewAmsterdam Pharma Company NV's revenue for the next 6 years is 27%.

N/A
Past Growth
27%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
NewAmsterdam Pharma Company NV

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
NewAmsterdam Pharma Company NV

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is NAMS's stock price target?
Price Target
49.74 USD

According to Wall Street analysts, the average 1-year price target for NAMS is 49.74 USD with a low forecast of 37.37 USD and a high forecast of 63 USD.

What is NewAmsterdam Pharma Company NV's Revenue forecast?
Projected CAGR
27%

The compound annual growth rate of NewAmsterdam Pharma Company NV's revenue for the next 6 years is 27%.

Back to Top